Tetra Natural Health Adds New Leaders to its Commercial Operations
January 14 2019 - 8:00AM
Derek Theriault, National Sales DirectorMichael
Olders, Director Operations and Logistics
Tetra Natural Health, a subsidiary of Tetra Bio-Pharma Inc., a
leader in cannabinoid-based drug discovery and development (TSX
VENTURE:TBP) (OTCQB:TBPMF), is pleased to announce that
Mr. Derek Theriault has been hired as National Sales Director
and Michael Olders has been hired as Director Operations and
Logistics.
Derek Theriault, National Sales
Director – has 20 years’ experience within the
pharmaceutical industry and has held various sales and leadership
roles during this time. He was pivotal to the launch of several
companies including the development of their sales forces and
penetration of the Canadian market. Derek has a proven track record
for strategically building market-share for several brand name
medications, over-the-counter (OTC) drugs and natural products.
Derek is recognized for his ability to lead sales teams as well as
to help grow the talent base within the organization while reaching
and surpassing the milestones that were set forth. He is also known
for his passion for coaching, his strong ethical standards and his
ability to respond to seize opportunities.
Michael Olders, Director Operations
and Logistics – With more than two
decades of experience, Michael has held several leadership
positions in Operations and Logistics in a variety of industries.
Having worked for small privately-owned businesses as well as large
multinational corporations, he is known for finding ways to
increase efficiencies while lowering costs, often using technology
to achieve significant positive results. Teamwork, communication
and integrity are hallmarks of Michael’s approach to growing
business and profits and exceeding goals. He studied at Selwyn
House School, Collège Brébeuf and McGill University, and is
passionate about continuous learning, technology, his family and
the Montreal Canadiens.
“I am very proud to add Derek Theriault and
Michael Olders to the Tetra Natural Health management team.
Their combined solid experience and track records with OTC drugs
and natural health products will enable us to grow our portfolio of
products and our commercial results significantly over the coming
year and contribute to the consolidated results of Tetra
Bio-Pharma,” says Richard Giguere, Chief Executive Officer of
Tetra Natural Health.
About Tetra Natural
Health:Tetra Natural Health inc. is a subsidiary of Tetra
Bio-Pharma inc. that focuses on identification, development and
marketing of hemp or cannabis-based natural health products, or
cannabinoids-based products authorized for sale by Health
Canada.
About Tetra Bio-Pharma:Tetra
Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) a biopharmaceutical leader
in cannabinoid-based drug discovery and development with
a Health Canada approved and FDA reviewed
clinical program aimed at bringing novel prescription drugs and
treatments to patients and their healthcare providers. Tetra
Bio-Pharma has subsidiaries engaged in the development of an
advanced and growing pipeline of Bio Pharmaceuticals, Natural
Health and Veterinary Products containing cannabis and other
medicinal plant-based elements. With patients at the core of its
mission, Tetra Bio-Pharma is focused on providing
rigorous scientific validation and safety data required for
inclusion into the existing bio pharma industry by regulators,
physicians and insurance companies. For more information
visit: www.tetrabiopharma.com
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-looking statementsSome statements in
this release may contain forward-looking information. All
statements, other than of historical fact, that address activities,
events or developments that the Company believes, expects or
anticipates will or may occur in the future (including, without
limitation, statements regarding potential acquisitions and
financings) are forward-looking statements. Forward-looking
statements are generally identifiable by use of the words "may",
"will", "should", "continue", "expect", "anticipate", "estimate",
"believe", "intend", "plan" or "project" or the negative of these
words or other variations on these words or comparable terminology.
Forward-looking statements are subject to a number of risks and
uncertainties, many of which are beyond the Company's ability to
control or predict, that may cause the actual results of the
Company to differ materially from those discussed in the
forward-looking statements. Factors that could cause actual results
or events to differ materially from current expectations include,
among other things, without limitation, the inability of the
Company to obtain sufficient financing to execute the Company's
business plan; competition; regulation and anticipated and
unanticipated costs and delays, the success of the Company's
research and development strategies, the applicability of the
discoveries made therein, the successful and timely completion and
uncertainties related to the regulatory process, the timing of
clinical trials, the timing and outcomes of regulatory or
intellectual property decisions and other risks disclosed in the
Company's public disclosure record on file with the relevant
securities regulatory authorities. Although the Company has
attempted to identify important factors that could cause actual
results or events to differ materially from those described in
forward-looking statements, there may be other factors that cause
results or events not to be as anticipated, estimated or intended.
Readers should not place undue reliance on forward-looking
statements. While no definitive documentation has yet been signed
by the parties and there is no certainty that such documentation
will be signed The forward-looking statements included in this news
release are made as of the date of this news release and the
Company does not undertake an obligation to publicly update such
forward-looking statements to reflect new information, subsequent
events or otherwise unless required by applicable securities
legislation.
More information
at: www.tetrabiopharma.com
For further information, please contact:Richard GiguèreChief
Executive OfficerTetra Natural Healthrgiguere@tetrabiopharma.com
For investors information, please contact:
investors@tetrabiopharma.com (438) 504-5784
Media Contact: Daniel Granger, C.M.ACJ CommunicationT.
514 840-7990M. 514 232
1556Daniel.granger@acjcommunication.com
Charlotte BlancheT. 514 840-1235 ext. 7772M. 514
914-0593c.blanche@acjcommunication.com
Two photos accompanying this announcement are
available
at: http://www.globenewswire.com/NewsRoom/AttachmentNg/7d0b2157-04d4-4cf9-9c4e-1321278ae8d5http://www.globenewswire.com/NewsRoom/AttachmentNg/6d9ea9f6-9ca3-4f8d-b8f1-ffbf17bff3d6
Tetra Bio Pharma (TSXV:TBP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tetra Bio Pharma (TSXV:TBP)
Historical Stock Chart
From Sep 2023 to Sep 2024